Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets53.56%
Miscellaneous
EmployeesN/A
Outstanding Shares128,570,000
Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions
What is Synthetic Biologics' stock symbol?
Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."
How were Synthetic Biologics' earnings last quarter?
Synthetic Biologics Inc (NYSEAMERICAN:SYN) posted its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.03. View Synthetic Biologics' Earnings History.
Are investors shorting Synthetic Biologics?
Synthetic Biologics saw a decrease in short interest in May. As of May 31st, there was short interest totalling 3,829,755 shares, a decrease of 4.1% from the May 15th total of 3,992,335 shares. Based on an average daily volume of 444,859 shares, the short-interest ratio is presently 8.6 days. Currently, 3.3% of the company's shares are sold short. View Synthetic Biologics' Current Options Chain.
Who are some of Synthetic Biologics' key competitors?
Some companies that are related to Synthetic Biologics include Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX), Oxford Biodynamics (OBD), Verseon (VSN), Silence Therapeutics (SLN), Trillium Therapeutics (TRIL), Tiziana Life Sciences (TILS), Bioventix (BVXP), Medicure Inc. Common Stock (MPH), Oncolytics Biotech (ONC), Kitrinor Metals (SCYB), Emblem (EMMBF) and Pfenex (PFNX).
Who are Synthetic Biologics' key executives?
Synthetic Biologics' management team includes the folowing people:
- Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)
- Dr. Joseph A. Sliman, Chief Medical Officer (Age 45)
- Vincent I. Perrone, Director of Corp. Communication
- Dr. Michael Kaleko M.D., Ph.D., Sr. VP of R&D
- Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing
Has Synthetic Biologics been receiving favorable news coverage?
News headlines about SYN stock have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Synthetic Biologics earned a media sentiment score of 0.07 on Accern's scale. They also assigned news stories about the company an impact score of 46.91 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Synthetic Biologics' major shareholders?
Which institutional investors are selling Synthetic Biologics stock?
Which institutional investors are buying Synthetic Biologics stock?
How do I buy shares of Synthetic Biologics?
Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synthetic Biologics' stock price today?
One share of SYN stock can currently be purchased for approximately $0.22.
How big of a company is Synthetic Biologics?
Synthetic Biologics has a market capitalization of $49.23 million.
How can I contact Synthetic Biologics?
Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.
MarketBeat Community Rating for Synthetic Biologics (SYN)
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days.
